Literature DB >> 19065418

Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis.

Sumru Onal1, Haluk Kazokoglu, Aylin Koc, Sule Yavuz.   

Abstract

PURPOSE: The authors report a case of necrotizing scleritis associated with Wegener's granulomatosis (WG), which was treated with rituximab for relapsing disease.
METHOD: Observational case report.
RESULTS: A 32-year-old male patient presented with necrotizing scleritis in his left eye. The patient was diagnosed as having limited WG. Cyclophosphamide was begun. Under maintenance treatment with azathioprine two relapses of scleritis occurred. Since a high cumulative dose of cyclophosphamide (22.5 g) was utilized initially, two intravenous infusions of rituximab 1 g was given. Complete resolution of scleritis occurred.
CONCLUSIONS: Rituximab may be effective to induce remission in patients with scleritis due to WG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19065418     DOI: 10.1080/09273940802331643

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  11 in total

Review 1.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

Review 2.  Biologic therapy for refractory scleritis: a new treatment perspective.

Authors:  Tania Sales de Alencar de Fidelix; Luis Antonio Vieira; Denise de Freitas; Virginia Fernandes Moça Trevisani
Journal:  Int Ophthalmol       Date:  2015-08-29       Impact factor: 2.031

Review 3.  Emerging drugs for uveitis.

Authors:  Theresa Larson; Robert B Nussenblatt; H Nida Sen
Journal:  Expert Opin Emerg Drugs       Date:  2011-01-06       Impact factor: 4.191

Review 4.  A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis.

Authors:  Neesurg S Mehta; Parisa Emami-Naeini
Journal:  J Ophthalmic Vis Res       Date:  2022-04-29

Review 5.  Pharmacotherapy of scleritis: current paradigms and future directions.

Authors:  Robert M Beardsley; Eric B Suhler; James T Rosenbaum; Phoebe Lin
Journal:  Expert Opin Pharmacother       Date:  2013-02-21       Impact factor: 3.889

Review 6.  Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.

Authors:  Sirichai Pasadhika; James T Rosenbaum
Journal:  Biologics       Date:  2014-02-15

Review 7.  Review of Systemic Immunosuppression for Autoimmune Uveitis.

Authors:  Claudia Castiblanco; C Stephen Foster
Journal:  Ophthalmol Ther       Date:  2014-03-18

8.  Peripheral Ulcerative Keratitis Associated with Granulomatosis with Polyangiitis Emerging Despite Cyclophosphamide, Successfully Treated with Rituximab.

Authors:  Yuya Fujita; Shoichi Fukui; Yushiro Endo; Sosuke Tsuji; Ayuko Takatani; Toshimasa Shimizu; Masataka Umeda; Ayako Nishino; Tomohiro Koga; Shin-Ya Kawashiri; Naoki Iwamoto; Kunihiro Ichinose; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Ryotaro Ueki; Masafumi Uematsu; Kaori Ishida; Kuniko Abe; Atsushi Kawakami
Journal:  Intern Med       Date:  2018-01-11       Impact factor: 1.271

9.  Conjunctivitis as a manifestation of Wegener's Granulomatosis.

Authors:  Mahmoud Nejabat; Golnoush Sadat Mahmoudi Nezhad; Saeedeh Shenavandeh; Mohammad Javad Ashraf; Mohammad Hassan Jalalpour
Journal:  J Curr Ophthalmol       Date:  2017-12-13

10.  Commentary: Rituximab in scleritis.

Authors:  Parthopratim Dutta Majumder
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.